Cold forming partnership leads to development of drug delivery system

Published: 26-Apr-2010
Drug Delivery Pharmaceutical

Dawson Shanahan and Zogenix work together on Sumavel DosePro

Cold forming expertise from Dawson Shanahan, a UK company based in Potters Bar, Hertfordshire, has been an essential part in the development of a needle-free syringe for pharmaceutical firm Zogenix.

Dawson Shanahan partnered Zogenix on development of the Sumavel DosePro (sumatriptan injection) system, a drug-device combination that enables needle-free delivery of subcutaneous sumatriptan for the acute treatment of migraines and cluster headaches.

‘Our client had heard of the benefits of cold forming in terms of both quality and manufacturing cost savings and approached us to produce one component of the DosePro device by cold forming,’ said Mark Jennings at Dawson Shanahan. ‘They were so impressed with our innovative solution that they then asked us to make a second component, again to demanding tolerances.’

Dawson Shanahan began to work closely with Zogenix to enhance the design of the DosePro system and manufactured a number of integral elements of the system in-house. With assistance from Simon West at E-Tech, the company created the bespoke machining and tooling needed to manufacture one of the components and together they developed and tested the parts until an optimum solution was found.

Dawson Shanahan engineered an aluminium chamber and steel ram to administer the drug without requiring a needle. The company says the success of the design is partly due to the high quality finish and intricate production of the cold-formed parts, which make it possible for the administration mechanism to work.

‘Throughout the manufacture process, Dawson Shanahan has been extremely collaborative, throwing the necessary resources at challenges to help us find the best solutions,’ said Bill Feinstein, director of operations planning and procurement at Zogenix.

Established in 1945, Dawson Shanahan employs 55 people in its 2,800m² purpose-built factory. The company is a precision manufacturer of components using cold forming, precision CNC machining and assembly. It specialises in the cold forming and finish machining of pure copper (OFHC), aluminium and ferrous components.

See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

Read more
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables

Trending Articles

  1. Lyocontract invests €50m in new freeze-drying facility with Syntegon vial line German CDMO Lyocontract has begun construction of a €50m expansion in Ilsenburg, partnering with Syntegon to install a complete vial filling and lyophilisation line for sterile freeze-dried pharmaceuticals
  2. Why weight sorting should move earlier in OSD development Phillip Ruda explains how earlier weight intelligence can improve process understanding, reduce risk and accelerate learning cycles
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    From proof-of-concept to commercial reality: a turning point for microneedle drug delivery A 50% reduction in microarray patch production costs demonstrates that scalable, automated MAP manufacturing is now commercially viable — clearing a critical barrier to mainstream pharmaceutical adoption
  4. SteinCares and Shilpa Biologicals sign licensing agreement to extend biosimilar access in Latin America The new partnership will combine Shilpa Biologicals' development and manufacturing capabilities with SteinCares' regional commercialisation platform and marks Shilpa's entry into the Latin American market
  5. Tablet-in-capsule technology: a versatile platform for complex oral solid dose development Tablet-in-capsule technology is redefining oral solid dosage development by enabling modular formulation design, differentiated release profiles and efficient fixed-dose combination strategies within a scalable, manufacturing-friendly platform

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates
Design & Build

Entries closed: what’s next for the Cleanroom Technology Awards?

With entries now closed, attention turns to the next phase of the awards programme
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities

The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258

The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
Drug Delivery

Palvella's QTORIN achieves positive Phase III results

Working in collaboration with MedPharm, the biopharma company announced positive topline results from its Phase 3 SELVA study of QTORIN rapamycin, paving the way for the company to prepare for commercial-scale manufacturing
Drug Delivery

New cancer drug delivery system boosts absorption of Paclitaxel

Researchers from Osaka Metropolitan University have developed a drug-delivery system that effectively delivers anticancer medication to cancerous tissues, potentially offering a solution for therapeutics that are difficult to absorb
Subscribe now